Compare Fox Corp Class B (FOX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Inovio Pharmaceuticals Inc — how do they compare? Fox Corp Class B trades at $59.02 (market cap $25.36B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: Fox Corp Class B is far larger — about 226× Inovio Pharmaceuticals Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FOX | INO | |
|---|---|---|
Market Cap | $25.36B | $112.19M |
Volume | 886,620 | 3,201,278 |
Sector | Media | Health |
52-Week High | $67.76 | $2.65 |
52-Week Low | $44.39 | $0.66 |
Typical Hold Time | 75 Days | 43 Days |
Enterprise Value | $28.72B | $83.51M |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a net income margin of 13.88% in 2025, highlight robust profitability. The company maintains solid cash flow and a healthy balance sheet with $5.35B in cash. Analyst consensus is a Buy with a $84.75 price target, though technical indicators show resistance near $57.
The stock presents a value opportunity with a P/E of 14.59 and P/S of 1.44, supported by earnings growth. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical trends. Upside potential exists if the company meets Q3 2026 EPS expectations of 2.06, but investors should monitor cash flow trends and competitive pressures in the media sector.
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
